Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01780974 · ClinicalTrials.gov registry record · Phase 1

Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention

A Phase 1 study, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 1
Development phase
42
Enrollment target

NCT01780974 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 42 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01780974, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 1
Development phase
42 participants
Enrollment target

Study Summary

The primary aim of the pilot study is to provide data that can be used to better determine sample size for the design of a larger clinical trial. The pilot will evaluate the effectiveness of Lipoic Acid (LA) plus Omega-3 fatty acids (Omega-3) on preventing Alzheimer's Disease (AD). The investigators will also collect data to evaluate recruitment rate, safety, and compliance over the 12 month study period.

Interventions

  • DRUG Placebo
  • DRUG Lipoic Acid plus Omega-3 Fatty Acids

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2013-04
Est. Completion 2015-10
Phase Phase 1

What the Registry Record Tells You About NCT01780974

The ClinicalTrials.gov registry entry for NCT01780974 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01780974 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01780974 about?

NCT01780974 is a clinical study titled "Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention". The primary aim of the pilot study is to provide data that can be used to better determine sample size for the design of a larger clinical trial. The pilot will evaluate the effectiveness of Lipoic Acid (LA) plus Omega-3 fatty acids (Omega-3) on preventing Alzheimer's Disease (AD). The investigators...

What is the current status of trial NCT01780974?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2013-04. Estimated completion is 2015-10.

What interventions are being tested in trial NCT01780974?

The interventions under investigation include: Placebo (DRUG), Lipoic Acid plus Omega-3 Fatty Acids (DRUG).

Who is sponsoring clinical trial NCT01780974?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.